Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Avadel Pharmaceuticals Plc ADR (AVDL)
Avadel Pharmaceuticals Plc ADR (AVDL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Avadel Pharmaceuticals Plc ADR 10 EARLSFORT TERRACE DUBLIN L2 D02 T380 IRL

www.avadel.com P: 353-1901-5201 F: 353-152-6107

Description:

Avadel Pharmaceuticals plc is a specialty pharmaceutical company. Its product pipeline consists of hospital and paediatrics. Hospital segment provides Bloxiverz(R), Vazculep(R) and Akovaz(TM). Paediatrics segment provides Karbinal (TM) ER, AcipHex(R) Sprinkle and Flexichamber(TM). The company operates primarily in Ireland, USA and France. Avadel Pharmaceuticals plc, formerly known as Flamel Technologies SA, is headquartered in Lyon, France.

Key Statistics

Overview:

Market Capitalization, $K 1,274,347
Enterprise Value, $K 1,329,657
Shares Outstanding, K 89,806
Annual Sales, $ 0 K
Annual Net Income, $ -137,460 K
Last Quarter Sales, $ 7,010 K
Last Quarter Net Income, $ -36,270 K
EBIT, $ -135,990 K
EBITDA, $ -134,500 K
60-Month Beta 1.55
% of Insider Shareholders 4.00%
% of Institutional Shareholders 71.23%
Float, K 86,214
% Float 96.00%
Short Volume Ratio 0.28

Growth:

1-Year Return 65.00%
3-Year Return 97.63%
5-Year Return 479.18%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth -838.71%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.41 on 11/08/23
Next Earnings Date N/A
Earnings Per Share ttm -2.03
EPS Growth vs. Prev Qtr 41.43%
EPS Growth vs. Prev Year -24.24%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

AVDL Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -306.46%
Return-on-Assets % -87.70%
Profit Margin % 0.00%
Net Margin % N/A
Debt/Equity 0.19
Price/Sales 122.18
Price/Cash Flow N/A
Price/Book 11.16
Book Value/Share 1.23
Interest Coverage -8.03
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar